Judit Anido

2.8k total citations · 1 hit paper
14 papers, 1.7k citations indexed

About

Judit Anido is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Judit Anido has authored 14 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Judit Anido's work include Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Cells and Metastasis (3 papers). Judit Anido is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Cells and Metastasis (3 papers). Judit Anido collaborates with scholars based in Spain, Canada and Palestinian Territory. Judit Anido's co-authors include José Baselga, Joaquı́n Arribas, Federico Rojo, Marta Guzmán, Maurizio Scaltriti, Serena Di Cosimo, Xavier Matías‐Guiu, Santiago Ramón y Cajal, Alberto Ocaña and Javier Cortés and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and JNCI Journal of the National Cancer Institute.

In The Last Decade

Judit Anido

12 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

2007 659 citations Maurizio Scaltriti, Federico Rojo et al. JNCI Journal of the National Cancer Institute profile →

Peers

Judit Anido

ONCOL

RNMI

PRM

Hakim Bouterfa Germany

Maria Niewolna United States

Maria Sundvall Finland

Rajiv Bassi United States

Natalia Sergina United States

WJ Gullick United Kingdom

Kendall D. Carey United States

Thinh Q. Pham United States

Astrid Kiermaier Switzerland

Dhara N. Amin United States

Hakim Bouterfa Germany

Judit Anido

1.0k ×0.8

ONCOL

573 ×0.8

491 ×0.8

RNMI

177 ×0.6

PRM

228 ×1.0

Citations per year, relative to Judit Anido Judit Anido (= 1×) peers Hakim Bouterfa

Countries citing papers authored by Judit Anido

Since Specialization

Citations

This map shows the geographic impact of Judit Anido's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judit Anido with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judit Anido more than expected).

Fields of papers citing papers by Judit Anido

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judit Anido. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judit Anido. The network helps show where Judit Anido may publish in the future.

Co-authorship network of co-authors of Judit Anido

This figure shows the co-authorship network connecting the top 25 collaborators of Judit Anido. A scholar is included among the top collaborators of Judit Anido based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judit Anido. Judit Anido is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Schram, Alison M., Erkut Borazanci, Irene Braña, et al.. (2020). Abstract CT147: Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors. Cancer Research. 80(16_Supplement). CT147–CT147. 3 indexed citations

Borazanci, Erkut, Alison M. Schram, Irene Braña, et al.. (2019). Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results. Annals of Oncology. 30. v487–v488.

Sinclair, Angus M., Robin Hallett, Patricia Giblin, et al.. (2018). Abstract 1751: MSC-1 is a first-in-class humanized monoclonal antibody that modulates the tumor microenvironment by inhibiting a novel cancer immunotherapy target, LIF. Cancer Research. 78(13_Supplement). 1751–1751. 1 indexed citations

Magram, Jeanne, Naimish Pandya, Kimberly Hoffman, et al.. (2018). Abstract LB-B34: LIF as a novel cancer immunotherapy target: modulating the tumor microenvironment with MSC-1, a humanized anti-LIF monoclonal antibody. Molecular Cancer Therapeutics. 17(1_Supplement). LB–B34.

Hyman, David M., Irene Braña, Anna Spreafico, et al.. (2018). A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS2602–TPS2602. 5 indexed citations

Anido, Judit, José A. Esté, Bonaventura Clotet, et al.. (2012). Noncyclam Tetraamines Inhibit CXC Chemokine Receptor Type 4 and Target Glioma-Initiating Cells. Journal of Medicinal Chemistry. 55(17). 7560–7570. 9 indexed citations

Anido, Judit, Andrea Sáez‐Borderías, Alba Gonzàlez-Juncà, et al.. (2010). Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. 18(6). 655–668. 5 indexed citations

Anido, Judit, Andrea Sáez‐Borderías, Alba Gonzàlez-Juncà, et al.. (2010). 40 TGFβ receptor inhibitors target the CD44high/Id1high glioma stem cell population in human glioblastoma. European Journal of Cancer Supplements. 8(5). 10–11. 1 indexed citations

Peñuelas, Silvia, Judit Anido, Gerard Folch, et al.. (2009). TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma. Cancer Cell. 15(4). 315–327. 419 indexed citations

10.

Scaltriti, Maurizio, Federico Rojo, Alberto Ocaña, et al.. (2007). Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute. 99(8). 628–638. 659 indexed citations breakdown →

11.

Anido, Judit, et al.. (2006). Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation. The EMBO Journal. 25(13). 3234–3244. 164 indexed citations

12.

Cosimo, Serena Di, Joan Seoane, Marta Guzmán, et al.. (2005). Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. Journal of Clinical Oncology. 23(16_suppl). 3112–3112. 13 indexed citations

13.

Anido, Judit, Pablo Matar, Joan Albanell, et al.. (2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.. PubMed. 9(4). 1274–83. 213 indexed citations

14.

Albanell, Joan, Jordi Codony‐Servat, Federico Rojo, et al.. (2001). Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.. PubMed. 61(17). 6500–10. 235 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact